Human Longevity offers tools for early disease detection and personalised treatment. Credit: Verin / Shutterstock.

Global private equity company TVM Capital Healthcare has made an equity investment in Human Longevity, a US-based company that specialises in precision medicine and healthy ageing.

The financial details of the investment remain undisclosed.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The deal aims to bolster Human Longevity’s growth in the US and facilitate its expansion into Saudi Arabia and South-East Asia.

It has been channelled through the Saudi Arabia-focused TVM Healthcare Afiyah Fund, which is the country’s largest growth capital fund of its kind.

Human Longevity plans to use the funding to enter the Saudi Arabian market, aligning with the nation’s Vision 2030 plan and Health Sector Transformation Program.

TVM said that Saudi Arabia’s healthcare strategy is shifting from traditional ‘sick care’ to a more holistic ‘health care’ approach, prioritising areas such as oncology, neurology, and cardiovascular disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Human Longevity co-founder and chief scientific adviser Dr Craig Venter said: “Human Longevity is a health firm where the goal is to stay ahead of ageing and illness.

“TVM Capital Healthcare’s investment enables us to strengthen our position globally as the most data-backed longevity practice, as well as establishes our foothold in markets, like Saudi Arabia and South-East Asia, that see the potential of our approach in preventive medicine and the huge impact it will have on changing cost of medicine.”

Based in California, Human Longevity is built on the principle of extending health spans and leveraging genomic science to prevent avoidable diseases.

The company has developed tools for early disease detection and personalised treatment, which aim to encourage predictive and preventative approaches to healthcare.

TVM Capital Healthcare chairman and CEO Dr Helmut Schuehsler said: “With our investment in HLI, we contribute to the transition towards the ‘healthcare of the future’, which is all about precision medicine, personalised care, and disease prevention.”